PURPOSE: Enzyme replacement therapy in infants with Pompe disease prolongs survival, decreases cardiomegaly, and improves muscle function. Because ectopy has been previously described in these patients, we sought to determine the prevalence and types of arrhythmias. METHODS: Thirty-eight children with infantile Pompe disease received enzyme replacement therapy in two open-label, multicenter, international, clinical trials. Data were reviewed on a retrospective basis. The corrected QT interval, ejection fraction, and indexed left ventricular mass were measured on a scheduled basis from electrocardiograms and echocardiograms. Arrhythmias were identified and characterized from electrocardiograms, ambulatory electrocardiograms, and point-of-care monitoring. Electrocardiogram and echocardiogram measurements were compared in children with and without arrhythmias. RESULTS: Seven children (18%) experienced arrhythmias. The QT interval, ejection fraction, indexed left ventricular mass, and rate of reduction of indexed left ventricular mass were not statistically different in those seven versus the other 31 children. Two children with life-threatening arrhythmias had among the highest combined baseline maximum indexed left ventricular mass and QT interval. Their arrhythmias occurred during severe metabolic stress from noncardiac illness. CONCLUSIONS: There was a high incidence of arrhythmias in our cohort. The relationship of arrhythmias with enzyme replacement therapy, myocardial fibrosis, or simply longer survival is unknown. Therefore, further characterization of specific arrhythmia risk factors and continued vigilance regarding screening for arrhythmias in children receiving enzyme replacement therapy is warranted.
PURPOSE: Enzyme replacement therapy in infants with Pompe disease prolongs survival, decreases cardiomegaly, and improves muscle function. Because ectopy has been previously described in these patients, we sought to determine the prevalence and types of arrhythmias. METHODS: Thirty-eight children with infantile Pompe disease received enzyme replacement therapy in two open-label, multicenter, international, clinical trials. Data were reviewed on a retrospective basis. The corrected QT interval, ejection fraction, and indexed left ventricular mass were measured on a scheduled basis from electrocardiograms and echocardiograms. Arrhythmias were identified and characterized from electrocardiograms, ambulatory electrocardiograms, and point-of-care monitoring. Electrocardiogram and echocardiogram measurements were compared in children with and without arrhythmias. RESULTS: Seven children (18%) experienced arrhythmias. The QT interval, ejection fraction, indexed left ventricular mass, and rate of reduction of indexed left ventricular mass were not statistically different in those seven versus the other 31 children. Two children with life-threatening arrhythmias had among the highest combined baseline maximum indexed left ventricular mass and QT interval. Their arrhythmias occurred during severe metabolic stress from noncardiac illness. CONCLUSIONS: There was a high incidence of arrhythmias in our cohort. The relationship of arrhythmias with enzyme replacement therapy, myocardial fibrosis, or simply longer survival is unknown. Therefore, further characterization of specific arrhythmia risk factors and continued vigilance regarding screening for arrhythmias in children receiving enzyme replacement therapy is warranted.
Authors: Zhi-hong Sun; Juha-Matti Happonen; Rolf Bennhagen; Heikki Sairanen; Erkki Pesonen; Lauri Toivonen; Eero Jokinen Journal: Am J Cardiol Date: 2004-07-01 Impact factor: 2.778
Authors: P Charron; E Villard; P Sébillon; P Laforêt; T Maisonobe; L Duboscq-Bidot; N Romero; V Drouin-Garraud; T Frébourg; P Richard; B Eymard; M Komajda Journal: Heart Date: 2004-08 Impact factor: 5.994
Authors: Richard J Ing; D Ryan Cook; Resai A Bengur; Eric A Williams; John Eck; Guy de L Dear; Allison K Ross; Frank H Kern; Priya S Kishnani Journal: Paediatr Anaesth Date: 2004-06 Impact factor: 2.556
Authors: Vickas V Patel; Michael Arad; Ivan P G Moskowitz; Colin T Maguire; Dorothy Branco; J G Seidman; Christine E Seidman; Charles I Berul Journal: J Am Coll Cardiol Date: 2003-09-03 Impact factor: 24.094
Authors: Piers C A Barker; Sara K Pasquali; Stephen Darty; Richard J Ing; Jennifer S Li; Raymond J Kim; Stephanie DeArmey; Priya S Kishnani; Michael J Campbell Journal: Mol Genet Metab Date: 2010-07-23 Impact factor: 4.797
Authors: Mary-Alice Abbott; Sean N Prater; Suhrad G Banugaria; Susan M Richards; Sarah P Young; Amy S Rosenberg; Priya S Kishnani Journal: Mol Genet Metab Date: 2011-08-11 Impact factor: 4.797
Authors: Kunil K Raval; Ran Tao; Brent E White; Willem J De Lange; Chad H Koonce; Junying Yu; Priya S Kishnani; James A Thomson; Deane F Mosher; John C Ralphe; Timothy J Kamp Journal: J Biol Chem Date: 2014-12-08 Impact factor: 5.157
Authors: Sean N Prater; Suhrad G Banugaria; Stephanie M DeArmey; Eleanor G Botha; Erin M Stege; Laura E Case; Harrison N Jones; Chanika Phornphutkul; Raymond Y Wang; Sarah P Young; Priya S Kishnani Journal: Genet Med Date: 2012-04-26 Impact factor: 8.822
Authors: Daniel Forsha; Jennifer S Li; P Brian Smith; Ans T van der Ploeg; Priya Kishnani; Sara K Pasquali Journal: Genet Med Date: 2011-07 Impact factor: 8.822
Authors: Punita Gupta; Brian J Shayota; Ankit K Desai; Fuad Kiblawi; Dorothy Myridakis; John Messina; Peter Tah; Lorien Tambini-King; Priya S Kishnani Journal: Front Immunol Date: 2020-09-04 Impact factor: 7.561